Article
β2-adrenoceptor activation enhances pyridostigmine efficacy in presynaptic congenital myasthenic syndrome
2026-05-12
Abstract excerpt
<b>Background and Purpose</b> Congenital myasthenic syndromes (CMS) are inherited disorders of neuromuscular transmission characterized by lifelong muscle weakness and fatigability. Variants in <i>SLC18A3</i>, encoding the vesicular acetylcholine transporter (VAChT), cause a severe presynaptic CMS with limited treatment options. Acetylcholinesterase inhibitors such as pyridostigmine are first-line therapy but ofte...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 05e42a64-1510-5f13-ae05-6f048d3bc71e
- DOI
- 10.22541/authorea.15003132/v1
